LOGIN  |  REGISTER
Cue Biopharma
Terns Pharmaceuticals

Viatris to Participate in Upcoming Investor Conferences

May 22, 2025 | Last Trade: US$9.26 0.06 0.65

PITTSBURGH, May 22, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two upcoming healthcare conferences in June 2025.

The Company will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2025, at 8:10 a.m. ET.

In addition, the Company will take part in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on June 9, 2025, at 10:40 a.m. ET.

Investors and the general public are invited to listen to both sessions at their respective times at investor.viatris.com. An archived version of each session will be available following the live event and can be accessed at the same location for a limited time.

About Viatris

Viatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedInInstagramYouTube and X.

 

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page